# Deficient butyrate-producing capacity in the gut microbiome is associated with bacterial network disturbances and fatigue symptoms in ME/CFS

**Authors:** Guo C, Che X, Briese T, Ranjan A, Allicock O, Yates RA, Cheng A, March D, Hornig M, Komaroff AL, Levine S, Bateman L, Vernon SD, Klimas NG, Montoya JG, Peterson DL, Lipkin WI, Williams BL

**Journal:** Cell Host & Microbe, 2023, 31(2):288-304.e8

**DOI:** 10.1016/j.chom.2023.01.004

**PMID:** 36758522

**PMCID:** PMC10183837

## Key Points

- **Major finding:** ME/CFS patients show deficient butyrate-producing capacity in gut microbiome
- **Specific bacteria reduced:** Faecalibacterium prausnitzii and Eubacterium rectale
- **Functional confirmation:** Multiple methods (functional metagenomics, qPCR, metabolomics) confirmed reduced butyrate synthesis
- **Clinical correlation:** F. prausnitzii abundance inversely associated with fatigue severity (more bacteria = less fatigue)
- **Multi-site validation:** 106 ME/CFS patients and 91 healthy controls across multiple geographic locations

## Methodology

- **Study design:** Multi-omic cross-sectional analysis
- **Sample size:** n=106 ME/CFS patients, n=91 healthy controls
- **Methods:**
  - Shotgun metagenomic sequencing
  - Functional metagenomics
  - qPCR for bacterial quantification
  - Targeted metabolomics (SCFA quantification)
  - Machine learning classification
- **Sites:** Multiple geographic locations (multi-center study)
- **Controls:** Age and sex-matched healthy controls

## Main Findings

### Butyrate-Producing Bacteria

1. **Faecalibacterium prausnitzii:** Significantly reduced in ME/CFS
2. **Eubacterium rectale:** Significantly reduced in ME/CFS
3. Both are recognized as abundant butyrate producers in healthy gut microbiome

### Functional Dysbiosis

- Not just compositional changes, but functional alterations
- Deficient microbial capacity for butyrate synthesis confirmed by:
  - Functional gene analysis (metagenomics)
  - Direct bacterial quantification (qPCR)
  - Metabolite measurement (fecal SCFA levels)

### Clinical Associations

- **Fatigue severity:** Inverse correlation with F. prausnitzii abundance
- **Bacterial network disturbances:** Altered microbial interactions in ME/CFS
- **Machine learning:** Successfully classified disease status based on bacterial patterns

## Mechanistic Implications

### Butyrate Functions

- Primary energy source for colonocytes (intestinal epithelial cells)
- Provides up to 70% of energy needed by colon cells
- Maintains gut barrier integrity
- Anti-inflammatory properties via HDAC inhibition
- Immune modulation

### Potential Pathophysiology Links

- Reduced butyrate â†’ impaired gut barrier function
- Increased intestinal permeability ("leaky gut")
- Bacterial translocation and endotoxemia
- Systemic inflammation
- Immune dysregulation
- Altered energy metabolism

## Clinical Implications

- Gut microbiome alterations are functionally significant in ME/CFS
- Butyrate-producing bacteria may be therapeutic targets
- Dietary interventions to increase butyrate production (resistant starch, prebiotics)
- Probiotic supplementation with butyrate-producing strains
- Fecal microbiota transplantation (FMT) consideration
- Potential biomarker for disease classification

## Limitations

- Cross-sectional design (cannot establish causality)
- Geographic variations in microbiome composition
- Diet not fully controlled/standardized
- Unclear if dysbiosis is cause or consequence of ME/CFS
- No intervention/treatment trial component

## Integration Points

### Chapter 5: Disease Course and Natural History
- Microbiome dysbiosis as persistent feature of disease
- Potential biomarker for disease severity

### Chapter 6: Pathophysiological Mechanisms
- Gut dysbiosis and butyrate deficiency as mechanistic pathway
- Links to immune dysfunction, inflammation, energy metabolism

### Chapter 7: Energy Metabolism and Mitochondrial Dysfunction
- Butyrate as energy substrate for colonocytes
- Potential systemic metabolic effects

### Chapter 9: Immune and Inflammatory Mechanisms
- Butyrate's anti-inflammatory and immunomodulatory properties
- Gut barrier dysfunction and bacterial translocation

### Chapter 15: Dietary and Lifestyle Interventions
- Evidence-based rationale for butyrate-enhancing dietary strategies
- Resistant starch, prebiotics, fermented foods

## Certainty Assessment

- **Study Quality:** HIGH (peer-reviewed, Cell Host & Microbe, multi-omic approach)
- **Sample Size:** Good (n=106 ME/CFS, n=91 controls)
- **Replication:** Confirmed by multiple methods within study; consistent with other ME/CFS microbiome studies
- **Conflicts of Interest:** Standard academic disclosures; NIH-funded
- **Limitations:** Cross-sectional design; causality not established

**Overall Certainty for Clinical Use:** MEDIUM-HIGH for mechanistic understanding; MEDIUM for therapeutic targets (requires intervention trials)
